Despite the limited number of tests conducted, KRAS mutations were detected in 3.33% (n = 5) of colorectal cancer (CRC) patients, while 7.33% exhibited the non-mutated or wild-type form, leaving 89.33% (n = 135) of cases classified as unknown. This evidence concerns the gene KRAS and colorectal cancer.